A Randomized Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH

  • End date
    Dec 18, 2022
  • participants needed
  • sponsor
    Enanta Pharmaceuticals
Updated on 18 June 2021
Nathalie Adda, MD
Primary Contact
Northeast GI Research Division (7.1 mi away) Contact
+85 other location
body mass index
fatty liver


A randomized, double-blind study to assess the safety and efficacy of EDP-305 in subjects with liver-biopsy proven Non-Alcoholic Steatohepatitis (NASH)

Condition Non Alcoholic Steatohepatitis
Treatment Placebo, EDP-305 1.5 mg, EDP-305 2 mg
Clinical Study IdentifierNCT04378010
SponsorEnanta Pharmaceuticals
Last Modified on18 June 2021


Yes No Not Sure

Inclusion Criteria

Informed consent documentation signed and dated by the subject
Male and female subjects, of all ethnic origins, between the ages of 18 and 75 years, inclusive
Subjects of all ethnic origins should have a Body Mass Index (BMI) > 25 kg/m2 and 45 except for Asian subjects who qualify for the study with BMI > 23kg/m2
Histological evidence of definite NASH based on NASH Clinical Research Network (CRN) criteria obtained from assessment of a liver biopsy by the central histopathologist. The biopsy may be obtained either 1) during the Screening window or 2) within 6 months prior to the Screening visit
NAFLD Activity Score (NAS) of 4 or greater with a score of at least 1 in each component of the NAS (steatosis scored 0-3, lobular inflammation scored 0-3, ballooning scored 0-2)
Fibrosis stage 2 or 3 using the NASH CRN Histologic Scoring System
Subjects must have Screening laboratory values for Hepatitis B surface antigen (HBsAg), anti-HCV antibodies and HCV RNA, and Human Immunodeficiency Virus (HIV) 1 and 2 antibodies (Ab) as seronegative. [Note: subjects previously infected by chronic hepatitis C and treated with direct acting antivirals (DAAs) with sustained virologic response (SVR) for at least 3 years will be allowed.]
A woman of childbearing potential who is sexually active with a male must agree to use two effective methods of contraception from the date of Screening until 30 days after the last dose of study drug
A male subject who has not had a vasectomy and is sexually active with a woman of childbearing potential must agree to use effective contraception from the date of Screening to 90 days after the last dose of study drug
Subject must be willing and able to adhere to the assessments, visit schedules, prohibitions and restrictions, as described in this protocol

Exclusion Criteria

Laboratory Screening results as indicated below
Total white blood cells (WBC) <3000 cells/mm3
Absolute neutrophil count (ANC) <1500 cells/mm3
Platelet count <140,000/mm3
International Normalized Ratio, INR >1.2 (unless due to use of anticoagulants)
Estimated glomerular filtration rate (eGFR) < 60 mL/min according to the Modification of Diet in Renal Disease (MDRD) equation
Total bilirubin > 1.5 times ULN during Screening. [Note: Patients with Gilbert's syndrome will be allowed following review by the Medical Monitor if they have a known history of Gilbert's syndrome with a normal direct bilirubin value and normal reticulocyte count.]
Pregnant or nursing females
MELD: Model for End-stage Liver Disease score >12\
Clinical or laboratory evidence of known chronic liver disease such as alcoholic liver disease, primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), autoimmune hepatitis, Wilson disease, iron overload, alpha-1-antitrypsin deficiency, drug-induced liver injury, known or suspected hepatocellular carcinoma (HCC)
History of acute liver complications due to gallstones (e.g., acute cholecystitis or acute biliary obstruction) unless the subject has had a cholecytectomy (more than 3 months prior to screening)
History of liver transplant, or current placement on a liver transplant list
Hepatorenal syndrome (type I or II)
Prior variceal hemorrhage, uncontrolled encephalopathy, liver cirrhosis Child-Pugh Class A, B, and C, esophageal varices, or refractory ascites within the previous 6 months of Screening and/or histological presence of liver cirrhosis
Prior or planned ileal resection, or prior or planned bariatric surgery. [Note: Subjects who have undergone gastric surgeries that do not affect drug absorption (e.g., gastric band or gastric sleeve procedures) will be allowed if they are stable for at least 1 year prior to Screening. Gastrectomy or Roux-en-Y bypass will be allowed if stable for at least 3 years prior to Screening.]
Subjects with clinically or otherwise documented cardiovascular or cerebrovascular disease including clinically significant anomalies of rhythm or pattern of ECG, that in the judgement of the Principal Investigator (PI) could affect the safety of the subject or their ability to comply with the study requirements
HbA1c 9.5% within 60 days prior to Day 1
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note